Diabetes Drug Slows Kidney Disease: DAPA-CKD Trial Stopped Early

AstraZeneca has announced that the phase 3 DAPA-CKD trial for dapagliflozin (Farxiga) in patients with chronic kidney disease has been halted early because of overwhelming efficacy.分類：chronic renal failure, chronic kidney failure, chronic kidney disease (ckd), chronic kidney disease, ckd,renal failure, renal insufficiency, kidney insufficiency, kidney failure,kidneys,diabetes mellitus,renal disease, kidney disease, kidney disorder, renal disorder, nephropathy,end stage renal disease (esrd), end stage renal disease, esrd,diabetes mellitus type 2, diabetes mellitus type ii, type...